ATE465738T1 - Neue kristalline formen der krebsbekämpfenden verbindung zd1839 - Google Patents
Neue kristalline formen der krebsbekämpfenden verbindung zd1839Info
- Publication number
- ATE465738T1 ATE465738T1 AT03708319T AT03708319T ATE465738T1 AT E465738 T1 ATE465738 T1 AT E465738T1 AT 03708319 T AT03708319 T AT 03708319T AT 03708319 T AT03708319 T AT 03708319T AT E465738 T1 ATE465738 T1 AT E465738T1
- Authority
- AT
- Austria
- Prior art keywords
- solvate
- compound
- trihydrate
- occurs
- designated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 6
- 239000012453 solvate Substances 0.000 abstract 6
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000004684 trihydrates Chemical class 0.000 abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 1
- UZILUDOSEVNVMU-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine methylsulfinylmethane Chemical compound ClC=1C=C(NC2=NC=NC3=CC(=C(C=C23)OCCCN2CCOCC2)OC)C=CC1F.CS(=O)C UZILUDOSEVNVMU-UHFFFAOYSA-N 0.000 abstract 1
- -1 ZD1839 trihydrate Chemical class 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0204392A GB0204392D0 (en) | 2002-02-26 | 2002-02-26 | Pharmaceutical compound |
| GB0212462A GB0212462D0 (en) | 2002-05-30 | 2002-05-30 | Pharmaceutical compound |
| PCT/GB2003/000794 WO2003072108A1 (en) | 2002-02-26 | 2003-02-24 | Novel crystalline forms of the anti-cancer compound zd1839 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465738T1 true ATE465738T1 (de) | 2010-05-15 |
Family
ID=27767099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03708319T ATE465738T1 (de) | 2002-02-26 | 2003-02-24 | Neue kristalline formen der krebsbekämpfenden verbindung zd1839 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7612077B2 (de) |
| EP (1) | EP1480650B1 (de) |
| JP (1) | JP4836404B2 (de) |
| KR (1) | KR20040086452A (de) |
| CN (1) | CN100404032C (de) |
| AT (1) | ATE465738T1 (de) |
| AU (1) | AU2003212500B2 (de) |
| BR (1) | BRPI0308023B1 (de) |
| CA (3) | CA2833470C (de) |
| DE (1) | DE60332322D1 (de) |
| ES (1) | ES2342660T3 (de) |
| IL (2) | IL163689A0 (de) |
| MX (1) | MXPA04008330A (de) |
| NO (1) | NO329618B1 (de) |
| NZ (1) | NZ534871A (de) |
| WO (1) | WO2003072108A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326569C (zh) * | 2002-02-26 | 2007-07-18 | 阿斯特拉曾尼卡有限公司 | 含有水溶性纤维素衍生物的iressa药物制剂 |
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| WO2006090413A1 (en) * | 2005-02-23 | 2006-08-31 | Natco Pharma Limited | Novel crystalline form of gefitinib and a process for its preparation |
| TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| WO2011100692A1 (en) | 2010-02-15 | 2011-08-18 | The General Hospital Corporation | Methods and devices for selective disruption of visceral fat by controlled cooling |
| CN101973944B (zh) * | 2010-10-14 | 2012-07-04 | 江苏先声药物研究有限公司 | 一种Gefitinib Form 1 晶型的制备方法 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| US8395552B2 (en) | 2010-11-23 | 2013-03-12 | Metamagnetics, Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
| RU2593231C2 (ru) | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Способы лечения с использованием селективных ингибиторов bcl-2 |
| CN103319422B (zh) * | 2012-03-21 | 2016-05-04 | 石药集团中奇制药技术（石家庄）有限公司 | 一种吉非替尼晶型及其制备方法 |
| WO2014016848A2 (en) | 2012-07-24 | 2014-01-30 | Laurus Labs Private Limited | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof |
| CN103896862B (zh) * | 2012-12-25 | 2017-05-10 | 江苏天士力帝益药业有限公司 | 一种吉非替尼Form 1晶型的制备方法 |
| CN103896863B (zh) * | 2012-12-26 | 2017-06-13 | 亚宝药业集团股份有限公司 | 抗癌化合物zd1839的晶型及其制备方法 |
| CN103896861A (zh) * | 2012-12-26 | 2014-07-02 | 亚宝药业集团股份有限公司 | 抗癌化合物zd1839的无定形物及其制备方法 |
| CN103910690A (zh) * | 2013-01-06 | 2014-07-09 | 上海科胜药物研发有限公司 | 一种吉非替尼新晶型及其制备方法 |
| CN103102316A (zh) * | 2013-01-17 | 2013-05-15 | 李彦 | ZD1839Form 1晶型的制备方法 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103360326B (zh) * | 2013-04-19 | 2016-03-30 | 南京优科生物医药研究有限公司 | 吉非替尼晶型i的精制方法 |
| US20140357723A1 (en) * | 2013-05-29 | 2014-12-04 | Uwe-Bernd Bernd Ross | Tricholine Nasal Formulation and Method of Use |
| KR20150001936A (ko) * | 2013-06-28 | 2015-01-07 | 제일약품주식회사 | 게피티닙의 신규한 결정형 및 이의 제조방법 |
| WO2015170345A1 (en) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | Pharmaceutical cocrystals of gefitinib |
| US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| WO2016033384A1 (en) * | 2014-08-28 | 2016-03-03 | The General Hospital Corporation | Injectable slurries and methods of manufacturing and using the same |
| US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| CN104277005A (zh) * | 2014-09-19 | 2015-01-14 | 成都新恒创药业有限公司 | 一种吉非替尼Form 1晶型的制备方法 |
| EP3233064A1 (de) | 2014-12-19 | 2017-10-25 | Synthon BV | Pharmazeutische zusammensetzung mit gefifinib |
| JP6871255B2 (ja) * | 2015-12-30 | 2021-05-12 | シントン・ベスローテン・フェンノートシャップ | ゲフィチニブの結晶形ａを製造する方法 |
| DK3419572T3 (da) | 2016-02-26 | 2026-06-29 | Massachusetts Gen Hospital | Systemer og fremgangsmåder til fremstilling og administrering af medicinsk isopslæmning |
| CN106083739B (zh) * | 2016-05-31 | 2019-05-14 | 华南理工大学 | 吉非替尼新晶型及其基于超临界反溶剂技术的制备方法 |
| CN111454221B (zh) * | 2020-04-21 | 2023-01-06 | 华南理工大学 | 一种吉非替尼和布美他尼药物共晶体及其制备方法 |
| CN118221596A (zh) * | 2020-06-15 | 2024-06-21 | 山东新时代药业有限公司 | 一种吉非替尼的有机酸盐 |
| US11241330B1 (en) | 2021-04-02 | 2022-02-08 | Brixton Biosciences, Inc. | Apparatus for creation of injectable slurry |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
| CN1326569C (zh) | 2002-02-26 | 2007-07-18 | 阿斯特拉曾尼卡有限公司 | 含有水溶性纤维素衍生物的iressa药物制剂 |
-
2003
- 2003-02-24 NZ NZ534871A patent/NZ534871A/en not_active IP Right Cessation
- 2003-02-24 ES ES03708319T patent/ES2342660T3/es not_active Expired - Lifetime
- 2003-02-24 KR KR10-2004-7013341A patent/KR20040086452A/ko not_active Ceased
- 2003-02-24 CN CNB038091623A patent/CN100404032C/zh not_active Expired - Lifetime
- 2003-02-24 AT AT03708319T patent/ATE465738T1/de not_active IP Right Cessation
- 2003-02-24 CA CA2833470A patent/CA2833470C/en not_active Expired - Lifetime
- 2003-02-24 IL IL16368903A patent/IL163689A0/xx active IP Right Grant
- 2003-02-24 MX MXPA04008330A patent/MXPA04008330A/es active IP Right Grant
- 2003-02-24 BR BRPI0308023-4A patent/BRPI0308023B1/pt not_active IP Right Cessation
- 2003-02-24 JP JP2003570854A patent/JP4836404B2/ja not_active Expired - Lifetime
- 2003-02-24 WO PCT/GB2003/000794 patent/WO2003072108A1/en not_active Ceased
- 2003-02-24 DE DE60332322T patent/DE60332322D1/de not_active Expired - Lifetime
- 2003-02-24 CA CA2477350A patent/CA2477350C/en not_active Expired - Lifetime
- 2003-02-24 US US10/505,690 patent/US7612077B2/en not_active Expired - Fee Related
- 2003-02-24 EP EP03708319A patent/EP1480650B1/de not_active Expired - Lifetime
- 2003-02-24 AU AU2003212500A patent/AU2003212500B2/en not_active Expired
- 2003-02-24 CA CA2702297A patent/CA2702297C/en not_active Expired - Lifetime
-
2004
- 2004-08-23 IL IL163689A patent/IL163689A/en unknown
- 2004-09-24 NO NO20044047A patent/NO329618B1/no not_active IP Right Cessation
-
2009
- 2009-09-17 US US12/561,835 patent/US20100137304A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60332322D1 (de) | 2010-06-10 |
| NO329618B1 (no) | 2010-11-22 |
| MXPA04008330A (es) | 2004-11-26 |
| CA2702297A1 (en) | 2003-09-04 |
| CA2477350A1 (en) | 2003-09-04 |
| US20050209229A1 (en) | 2005-09-22 |
| IL163689A0 (en) | 2005-12-18 |
| EP1480650A1 (de) | 2004-12-01 |
| CN100404032C (zh) | 2008-07-23 |
| AU2003212500A1 (en) | 2003-09-09 |
| AU2003212500B2 (en) | 2008-01-03 |
| HK1070582A1 (en) | 2005-06-24 |
| CA2702297C (en) | 2014-02-04 |
| NO20044047L (no) | 2004-11-16 |
| EP1480650B1 (de) | 2010-04-28 |
| JP4836404B2 (ja) | 2011-12-14 |
| WO2003072108A1 (en) | 2003-09-04 |
| US7612077B2 (en) | 2009-11-03 |
| IL163689A (en) | 2011-10-31 |
| KR20040086452A (ko) | 2004-10-08 |
| CN1652790A (zh) | 2005-08-10 |
| US20100137304A1 (en) | 2010-06-03 |
| CA2477350C (en) | 2013-02-12 |
| NZ534871A (en) | 2007-05-31 |
| ES2342660T3 (es) | 2010-07-12 |
| BRPI0308023B1 (pt) | 2021-07-27 |
| JP2005525354A (ja) | 2005-08-25 |
| CA2833470C (en) | 2016-03-29 |
| BR0308023A (pt) | 2004-12-28 |
| CA2833470A1 (en) | 2003-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60332322D1 (de) | Neue kristalline formen der krebsbekämpfenden verbindung zd1839 | |
| ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
| MX2007005694A (es) | Nuevos derivados de betulina, preparacion y uso de los mismos. | |
| CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
| TW200602338A (en) | Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions | |
| CR8842A (es) | Derivados de pirido-pirimidina, su preparacion, su aplicacion en terapeutica | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| MY142018A (en) | Thiophene derivatives as chk 1 inihibitors | |
| ECSP066667A (es) | Derivados de ciclohexano espirociclicos | |
| CY1108573T1 (el) | Ανταγωνιστες νρυυ5 | |
| ATE297910T1 (de) | Retinoid x rezeptormodulatoren | |
| HUP0401982A2 (hu) | Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| AR022469A1 (es) | Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias | |
| NZ547565A (en) | Substituted arylpyrazoles as parasiticidal agents | |
| HN2003000417A (es) | Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico | |
| TW200603799A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
| PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
| TWI268280B (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| DE60114640D1 (en) | Antithrombosemittel | |
| TW200800962A (en) | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | |
| DE60215195D1 (de) | Derivate morphinähnlicher opioidverbindungen | |
| GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
| AR044320A1 (es) | Derivados 3-decladinosilo de la clase de 9a - n-carbamoil - y 9a-ntiocarbamoil- 9 dihidro-9a aza- 9a - homoeritromicina a | |
| WO2007004041A3 (en) | New compounds and their pharmaceutical use | |
| HUP0401895A2 (hu) | Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |